Equity
Additional Paid-In Capital
Bristol-Myers Squibb Additional Paid-In Capital increased by 0.3% to $46.27B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from $45.90B to $46.27B. Over 4 years (FY 2020 to FY 2024), Additional Paid-In Capital shows relatively stable performance with a 0.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
An increase typically signals recent equity financing activities or the issuance of shares for employee compensation.
Detailed definition
Additional paid-in capital represents the amount of capital received from investors in excess of the par value of the is...
Peer comparison
Common in all corporations; levels depend on the history of equity issuance and stock-based compensation.
Metric ID:
additional_paid_in_capitalHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $44.06B | $44.29B | $44.36B | $43.76B | $44.38B | $44.96B | $45.17B | $45.14B | $45.30B | $44.85B | $45.68B | $45.66B | $45.77B | $45.90B | $46.02B | $46.01B | $46.13B | $46.27B |
| QoQ Change | — | +0.5% | +0.2% | -1.4% | +1.4% | +1.3% | +0.5% | -0.1% | +0.4% | -1.0% | +1.9% | -0.1% | +0.2% | +0.3% | +0.3% | -0.0% | +0.3% | +0.3% |
| YoY Change | — | — | — | — | +0.7% | +1.5% | +1.8% | +3.2% | +2.1% | -0.2% | +1.1% | +1.1% | +1.0% | +2.3% | +0.7% | +0.8% | +0.8% | +0.8% |
Range$43.76B – $46.27B
CAGR+1.2%
Avg YoY Growth+1.3%
Median YoY Growth+1.1%
Current Streak2 quarters growth
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's additional paid-in capital?
- Bristol-Myers Squibb (BMY) reported additional paid-in capital of $46.27B in Q3 2025.
- How has Bristol-Myers Squibb's additional paid-in capital changed year-over-year?
- Bristol-Myers Squibb's additional paid-in capital increased by 0.8% year-over-year, from $45.90B to $46.27B.
- What is the long-term trend for Bristol-Myers Squibb's additional paid-in capital?
- Over 4 years (2020 to 2024), Bristol-Myers Squibb's additional paid-in capital has grown at a 0.9% compound annual growth rate (CAGR), from $44.33B to $46.02B.
- What does additional paid-in capital mean?
- Capital contributed by shareholders above the nominal par value of the stock.